Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.

Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M

Toxicologic pathology1 Jul 2004Cited by 253 (Europe PMC)

PMID15204966DOI10.1080/01926230490462138PepBankPUB-15204966

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In female F344 rats, teriparatide increased osteoma incidence after prolonged treatment.
In plain wordsIn rats, prolonged teriparatide treatment increased osteoma incidence.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteoma incidence
Study
ratn: not reported in source
Female F344 rats
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 microg/kg/d · 20 or 24 monthsAs given in this study (rat).
Source sentences
Summary
Significant increases in the incidence of bone tumors (osteoma, osteoblastoma, and osteosarcoma) occurred in rats treated with 30 microg/kg for 20 or 24 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions.
Summary · context
Treatment groups consisted of different combinations of dose (0, 5, or 30 microg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age).
Report a problemFND-1520496601
02AnimalAnimal study (in vivo)Safety outcome
In female F344 rats, teriparatide increased osteoblastoma incidence after prolonged treatment.
In plain wordsIn rats, prolonged teriparatide treatment increased osteoblastoma incidence.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteoblastoma incidence
Study
ratn: not reported in source
Female F344 rats
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 microg/kg/d · 20 or 24 monthsAs given in this study (rat).
Source sentences
Summary
Significant increases in the incidence of bone tumors (osteoma, osteoblastoma, and osteosarcoma) occurred in rats treated with 30 microg/kg for 20 or 24 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions.
Summary · context
Treatment groups consisted of different combinations of dose (0, 5, or 30 microg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age).
Report a problemFND-1520496602
03AnimalAnimal study (in vivo)Safety outcome
In female F344 rats, teriparatide increased osteosarcoma incidence after prolonged treatment.
In plain wordsIn rats, prolonged teriparatide treatment increased osteosarcoma incidence.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteosarcoma incidence
Study
ratn: not reported in source
Female F344 rats
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 microg/kg/d · 20 or 24 monthsAs given in this study (rat).
Source sentences
Summary
Significant increases in the incidence of bone tumors (osteoma, osteoblastoma, and osteosarcoma) occurred in rats treated with 30 microg/kg for 20 or 24 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions.
Summary · context
Treatment groups consisted of different combinations of dose (0, 5, or 30 microg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age).
Report a problemFND-1520496603
04AnimalAnimal study (in vivo)Safety outcome
In rats starting teriparatide at six months of age, no neoplasms occurred with the lower-dose regimen.
In plain wordsIn rats starting treatment at six months of age, no bone tumors occurred with the lower-dose teriparatide regimen.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableBone neoplasms
Study
ratn: not reported in source
Female F344 rats
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/d · 6 or 20 monthsAs given in this study (rat).
Source sentences
Summary
No neoplasms were found when the 5 microg/kg treatment was initiated at 6 months of age and continued for either 6 or 20 months (up to 70% of life span).
2 context sentences(design, population, supporting numbers)
Summary · context
A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions.
Summary · context
Treatment groups consisted of different combinations of dose (0, 5, or 30 microg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age).
Report a problemFND-1520496604
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, the teriparatide regimen without neoplasms substantially increased bone mass.
In plain wordsIn rats, the teriparatide regimen without bone tumors increased bone mass.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone mass
Study
ratn: not reported in source
Female F344 rats
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 microg/kg/d · 6 or 20 monthsAs given in this study (rat).
Source sentences
Summary
This treatment regimen defined a "no-effect" dose for neoplasm formation that nevertheless resulted in substantial increases in bone mass.
3 context sentences(design, population, supporting numbers)
Summary · context
No neoplasms were found when the 5 microg/kg treatment was initiated at 6 months of age and continued for either 6 or 20 months (up to 70% of life span).
Summary · context
A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions.
Summary · context
Treatment groups consisted of different combinations of dose (0, 5, or 30 microg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age).
Report a problemFND-1520496605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.